Etzer Darout
Stock Analyst at Barclays
(4.33)
# 408
Out of 5,093 analysts
150
Total ratings
50.82%
Success rate
18.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Overweight | $36 → $56 | $44.84 | +24.89% | 11 | Dec 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $70 → $119 | $87.54 | +35.94% | 4 | Dec 9, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $22 → $35 | $19.54 | +79.12% | 1 | Nov 24, 2025 | |
| KURA Kura Oncology | Maintains: Overweight | $11 → $28 | $10.70 | +161.68% | 1 | Nov 24, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $4 → $9 | $2.21 | +308.16% | 1 | Nov 24, 2025 | |
| INCY Incyte | Maintains: Overweight | $101 → $115 | $94.83 | +21.27% | 1 | Nov 24, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $44 → $45 | $44.31 | +1.56% | 7 | Nov 17, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Underweight | $25 → $21 | $28.02 | -25.05% | 2 | Nov 11, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $83 → $70 | $44.90 | +55.90% | 2 | Nov 11, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $58 → $56 | $36.00 | +55.56% | 3 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $88 | $89.73 | -1.93% | 4 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $48 | $15.44 | +210.88% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $16 | $13.25 | +20.75% | 6 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $41 | $41.44 | -1.06% | 5 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $6 → $23 | $16.92 | +35.93% | 7 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $17.18 | -6.87% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3.5 → $6 | $3.90 | +54.04% | 12 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $61 | $4.24 | +1,338.68% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $48 | $30.92 | +55.26% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $75.37 | +65.85% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $16 | $8.51 | +88.01% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $142 | $130.60 | +8.73% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $112 → $97 | $96.76 | +0.25% | 8 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $2.55 | +292.16% | 5 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $3 | $1.40 | +114.29% | 10 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $4.52 | +187.61% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $94.72 | +50.97% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $3.14 | -4.46% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $19.32 | +81.16% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $1.87 | +3,268.98% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $2.57 | +950.58% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $105.21 | +27.36% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $31.04 | +54.64% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $130.60 | -8.12% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.06 | +466.04% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $89.83 | -8.71% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.48 | +324.58% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $409.00 | -58.44% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $54.70 | -1.28% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $64.49 | -41.08% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $3.22 | +1,514.91% | 1 | Mar 28, 2018 |
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Overweight
Price Target: $36 → $56
Current: $44.84
Upside: +24.89%
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $70 → $119
Current: $87.54
Upside: +35.94%
Syndax Pharmaceuticals
Nov 24, 2025
Maintains: Overweight
Price Target: $22 → $35
Current: $19.54
Upside: +79.12%
Kura Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $10.70
Upside: +161.68%
Iovance Biotherapeutics
Nov 24, 2025
Maintains: Overweight
Price Target: $4 → $9
Current: $2.21
Upside: +308.16%
Incyte
Nov 24, 2025
Maintains: Overweight
Price Target: $101 → $115
Current: $94.83
Upside: +21.27%
Scholar Rock Holding
Nov 17, 2025
Maintains: Overweight
Price Target: $44 → $45
Current: $44.31
Upside: +1.56%
Celldex Therapeutics
Nov 11, 2025
Maintains: Underweight
Price Target: $25 → $21
Current: $28.02
Upside: -25.05%
AnaptysBio
Nov 11, 2025
Maintains: Overweight
Price Target: $83 → $70
Current: $44.90
Upside: +55.90%
RAPT Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $58 → $56
Current: $36.00
Upside: +55.56%
Nov 7, 2025
Maintains: Overweight
Price Target: $72 → $88
Current: $89.73
Upside: -1.93%
Nov 7, 2025
Maintains: Overweight
Price Target: $47 → $48
Current: $15.44
Upside: +210.88%
Nov 6, 2025
Maintains: Overweight
Price Target: $15 → $16
Current: $13.25
Upside: +20.75%
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $40 → $41
Current: $41.44
Upside: -1.06%
Oct 29, 2025
Upgrades: Overweight
Price Target: $6 → $23
Current: $16.92
Upside: +35.93%
Oct 21, 2025
Maintains: Underweight
Price Target: $13 → $16
Current: $17.18
Upside: -6.87%
Oct 21, 2025
Maintains: Overweight
Price Target: $3.5 → $6
Current: $3.90
Upside: +54.04%
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $4.24
Upside: +1,338.68%
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $30.92
Upside: +55.26%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $75.37
Upside: +65.85%
Oct 13, 2025
Initiates: Overweight
Price Target: $16
Current: $8.51
Upside: +88.01%
Oct 13, 2025
Initiates: Overweight
Price Target: $142
Current: $130.60
Upside: +8.73%
Sep 30, 2025
Downgrades: Equal-Weight
Price Target: $112 → $97
Current: $96.76
Upside: +0.25%
Sep 23, 2025
Maintains: Overweight
Price Target: $8 → $10
Current: $2.55
Upside: +292.16%
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.40
Upside: +114.29%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $4.52
Upside: +187.61%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $94.72
Upside: +50.97%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $3.14
Upside: -4.46%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $19.32
Upside: +81.16%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $1.87
Upside: +3,268.98%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $2.57
Upside: +950.58%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $105.21
Upside: +27.36%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $31.04
Upside: +54.64%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $130.60
Upside: -8.12%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.06
Upside: +466.04%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $89.83
Upside: -8.71%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.48
Upside: +324.58%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $409.00
Upside: -58.44%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $54.70
Upside: -1.28%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $64.49
Upside: -41.08%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $3.22
Upside: +1,514.91%